Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Cert. of designation
Quarterly results
Appointed COO
Appointed director

Perspective Therapeutics, Inc. (ISR) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/29/2021 GN Isoray To Announce Third Quarter Fiscal 2021 Financial Results on May 13, 2021
03/31/2021 GN University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection
03/03/2021 GN Isoray to Present at the Oppenheimer 31st Annual Healthcare Conference
02/16/2021 GN Isoray Announces the Appointment of Lisa Lauer As Vice President Business Development
02/09/2021 GN Isoray Announces Second Quarter Fiscal 2021 Financial Results
02/05/2021 GN Isoray To Announce Second Quarter Fiscal 2021 Financial Results on February 9, 2021
02/04/2021 GN Isoray Announces Pricing of $45 Million Public Offering
02/03/2021 GN Isoray Announces Proposed Underwritten Public Offering
01/07/2021 GN Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference
01/05/2021 GN C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray's Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
11/24/2020 GN Isoray's Cesium-131 Spotlighted in Multiple Presentations at ASTRO
11/02/2020 GN Isoray To Announce First Quarter Fiscal 2021 Financial Results on November 10, 2020
10/19/2020 GN Isoray, Inc. Announces Proposed Underwritten Public Offering
09/17/2020 GN Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2020 Financial Results
06/17/2020 GN Isoray and University of Cincinnati Physicians Company Sign Research Agreement to Study Treatment of Head and Neck Cancers 
06/02/2020 GN Second Ten Year Data Report Demonstrates Efficacy of Isoray's Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer
05/12/2020 GN Isoray Announces Record Third Quarter Fiscal 2020 Financial Results
05/12/2020 GN Centers for Medicare and Medicaid Services Approves Isoray's Application for Billing Codes for the Intraoperative Use of Cesium-131
01/31/2020 GN Isoray To Announce Second Quarter Fiscal 2020 Financial Results on February 11, 2020
10/31/2019 GN Isoray To Announce First Quarter Fiscal 2020 Financial Results on November 12, 2019
10/29/2019 GN Isoray Will Have Prominent Role at American Brachytherapy Society's Annual Prostate Brachytherapy Workshop
09/24/2019 GN Isoray Announces Fourth Quarter and Full-Year Fiscal 2019 Financial Results
09/12/2019 GN Isoray To Announce Fourth Quarter and Year End 2019 Financial Results on September 24, 2019
09/10/2019 GN Isoray To Spotlight Cesium-131 Advances in Treating Hard to Treat Cancers at the American Society for Radiation Oncology Annual Meeting 
06/12/2019 GN Isoray To Launch The Power of Blu Introducing A New Brand Identity at the American Brachytherapy Society's Annual Meeting
05/01/2019 GN Isoray To Announce Third Quarter Fiscal 2019 Financial Results on May 9, 2019
04/16/2019 GN Isoray Collaborates With Texas Oncology to Fill Void in Training Programs For Next Generation of Brachytherapists
02/12/2019 GN Isoray Announces Second Quarter Fiscal 2019 Financial Results
01/29/2019 GN Medical University of South Carolina Performs World's First Prostate Cancer Surgery Using Blu Build Brachytherapy System
12/17/2018 GN IsoRay Announces the Appointment of Lori Woods As Chief Executive Officer
12/03/2018 GN IsoRay Names Jonathan Hunt New Chief Financial Officer
11/26/2018 GN Report: Exploring Fundamental Drivers Behind Micron Solutions, Gentherm, ENSERVCO, IsoRay, Trilogy Metals, and Xtant Medical — New Horizons, Emerging Trends, and Upcoming Developments
10/24/2018 GN IsoRay To Announce First Quarter Fiscal 2019 Financial Results on November 8, 2018
09/25/2018 GN IsoRay Announces Fourth Quarter and Full-Year 2018 Financial Results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy